ZJYL Plummets 22.7%: What's Behind the Sudden Freefall in Jin Medical?

Summary
• Jin Medical (ZJYL) crashes 22.68% intraday to $0.2301, its lowest since the 52-week low of $0.215.
• Weiss Ratings downgrades ZJYL to 'sell (d+)' from 'hold (c-)', signaling bearish sentiment.
• Technical indicators show RSI at 15.05 (oversold), MACD (-0.067) and bearish histogram.

Jin Medical’s stock is in freefall, driven by a sharp downgrade and deteriorating technicals. The stock’s intraday range of $0.215–$0.243 highlights extreme volatility, while sector peers like Medtronic (MDT) show muted declines. Traders are scrambling to parse the catalysts behind this collapse.

Downgrade and Technical Deterioration Fuel Sell-Off
Weiss Ratings’ downgrade of ZJYL to 'sell (d+)' from 'hold (c-)' has triggered a liquidity crisis. The move follows a lack of positive news flow and deteriorating fundamentals, including a -202x dynamic P/E ratio and negative earnings. Technically, the stock is trapped below its 200-day MA ($0.697) and Bollinger Bands’ lower bound ($0.215), with RSI in oversold territory (15.05) and a bearish MACD crossover. This confluence of bearish signals has accelerated the selloff.

Medical Instruments & Supplies Sector Mixed as MDT Trails
The broader medical instruments sector shows mixed momentum, with Medtronic (MDT) down 0.36% despite ZJYL’s collapse. While ZJYL’s decline is idiosyncratic, the sector’s muted performance suggests broader caution. However, ZJYL’s 22.7% drop far outpaces MDT’s decline, indicating the move is driven by company-specific factors rather than sector-wide trends.

Bearish Setup: Short-Term Plays and ETF Implications
• 200-day MA: $0.697 (far below current price)
• RSI: 15.05 (oversold)
• Bollinger Bands: $0.215–$0.555 (stock at lower bound)
• MACD: -0.067 (bearish divergence)

ZJYL’s technicals scream short-term bearishness. Key support levels at $0.215 (52-week low) and $0.243 (intraday high) are critical. A breakdown below $0.215 could trigger a test of the $0.170 bid level. Given the absence of options liquidity and the stock’s extreme volatility, aggressive short-sellers might consider a cash-secured short at $0.2301 with a stop above $0.243. ETFs like XLV (healthcare) or XBI (medical devices) could mirror sector sentiment, but ZJYL’s standalone risk remains high.

Backtest Jin Medical Stock Performance
I attempted to construct the event list and run the back-test exactly as you requested (-23 % or worse intraday plunge from the previous close, 2022-01-01 → 2025-10-31). • Daily OHLC data for Jin Medical (ZJYL.O) were successfully downloaded. • I screened every session for “(day’s low – prior close) / prior close ≤ –23 %”. • The resulting date list turned out to be empty – the stock has not experienced an intraday draw-down of 23 % or more during the period examined. • Because the event list contained zero dates, the event_backtest_engine could not compute statistics and returned the error you saw (“min() arg is an empty sequence”).What this means1. From January 2022 through today there has been no trading day on which ZJYL’s intraday low stood 23 % or more below the previous close. 2. Consequently, we cannot run an event study on that specific trigger.How would you like to proceed?A. Loosen the trigger (e.g. –20 %, –15 %, –10 %). B. Use a different definition (e.g. close-to-close drop of ≥ 23 %). C. Examine a different ticker or a different time span. D. Stop here.Let me know which option works for you, and I will rerun the analysis accordingly.

ZJYL’s Freefall: Time to Flee or Fade the Breakdown?
ZJYL’s 22.7% collapse reflects a perfect storm of a downgrade and deteriorating technicals. While the stock is near its 52-week low, oversold RSI and bearish MACD suggest further downside is likely. Traders should monitor the $0.215 support level and Medtronic’s performance as a sector barometer. With MDT down 0.36%, the sector isn’t immune to broader risk-off sentiment. For now, ZJYL’s trajectory is dire—brace for a potential test of the $0.170 bid level.